Pharsight

1. Jenloga patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5869100	CONCORDIA PHARMS INC	Extended release clonidine formulation (tablet)	Oct, 2013 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-149)	Nov 20, 2017
New Product(NP)	Sep 28, 2013

Market Authorisation Date: 30 September, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.1 mg and 0.2 mg	04 Mar, 2011	1	02 Apr, 2014	13 Oct, 2013	Extinguished
0.1 mg and 0.2 mg	04 Mar, 2011	1	30 Sep, 2013	13 Oct, 2013	Eligible

Strength	Dosage	Availability
0.1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
0.2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5869100	CONCORDIA PHARMS INC	Extended release clonidine formulation (tablet)	Oct, 2013 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-149)	Nov 20, 2017
New Product(NP)	Sep 28, 2013

Market Authorisation Date: 30 September, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.1 mg and 0.2 mg	04 Mar, 2011	1	02 Apr, 2014	13 Oct, 2013	Extinguished
0.1 mg and 0.2 mg	04 Mar, 2011	1	30 Sep, 2013	13 Oct, 2013	Eligible

Strength	Dosage	Availability
0.2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
0.1MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6221392	CONCORDIA PHARMS INC	Rapidly dissolving robust dosage form	Apr, 2018 (6 years ago)
US6024981	CONCORDIA PHARMS INC	Rapidly dissolving robust dosage form	Apr, 2018 (6 years ago)
US6740341	CONCORDIA PHARMS INC	Taste masking rapid release coating system	Nov, 2019 (4 years ago)

Market Authorisation Date: 01 June, 2006

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
EQ 30MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
EQ 10MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
EQ 15MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription